Stock NXGL NEXGEL, INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : NEXGEL, Inc.

NEXGEL, Inc. Stock price

Equities

NXGL

US65344E1073

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 10:28:22 2023-12-04 am EST 		Intraday chart for NEXGEL, Inc. 5-day change 1st Jan Change
2.115 USD +1.20% +12.60% +68.00%
Nov. 13 NEXGEL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nov. 13 Transcript : NEXGEL, Inc., Q3 2023 Earnings Call, Nov 13, 2023 CI

Financials (USD)

Sales 2023 * 4.11M Sales 2024 * 6.64M Capitalization 11.95M
Net income 2023 * -2M Net income 2024 * - EV / Sales 2023 *
2,91x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 *
1,80x
P/E ratio 2023 *
-4,45x
P/E ratio 2024 *
-52,3x
Employees 12
Yield 2023 *
-
Yield 2024 *
-
Free-Float 76.27%
More Fundamentals * Assessed data

Chart NEXGEL, Inc.

Dynamic Chart

Latest news about NEXGEL, Inc.

NEXGEL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : NEXGEL, Inc., Q3 2023 Earnings Call, Nov 13, 2023 CI
Earnings Flash (NXGL) NEXGEL Reports Q3 Revenue $1.2M, vs. Street Est of $1.2M MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
NEXGEL Unit Executes Supply Agreement with AbbVie MT
NEXGEL, Inc. Secures Supply Agreement with AbbVie Inc CI
Transcript : NEXGEL, Inc., Q2 2023 Earnings Call, Aug 14, 2023 CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022. CI
NEXGEL, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (NXGL) NEXGEL Reports Q2 Revenue $1.2M, vs. Street Est of $1M MT
NEXGEL Partners With Enigma Health for Retail Distribution, Marketing Services in North America MT
NEXGEL, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (NXGL) NEXGEL Reports Q1 Revenue $620,000 MT
NEXGEL, Inc. Provides Revenue Guidance for the Second Quarter 2023 CI
Transcript : NEXGEL, Inc., Q1 2023 Earnings Call, May 15, 2023 CI
More news

Press releases NEXGEL, Inc.

NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year AQ
NEXGEL to Report Third Quarter 2023 Financial Results on November 13th AQ
NEXGEL Secures Supply Agreement with AbbVie AQ
NEXGEL to Participate in the LD Micro Main Event XVI on October 3rd AQ
NEXGEL Reports Second Quarter 2023 Record Revenue of $1.17 Million, an Increase of 108% Year-Over-Year AQ
More press releases

Quotes and Performance

1 day-0.24%
1 week+12.60%
Current month+11.11%
1 month+11.70%
3 months-16.00%
6 months-13.22%
Current year+68.00%
More quotes

Highs and lows

1 week
1.71
Extreme 1.7107
2.16
1 month
1.65
Extreme 1.65
2.16
Current year
1.18
Extreme 1.18
3.05
1 year
1.09
Extreme 1.09
3.05
3 years
1.09
Extreme 1.09
4.66
5 years
1.09
Extreme 1.09
4.66
10 years
1.09
Extreme 1.09
4.66
More quotes

Managers and Directors - NEXGEL, Inc.

Managers TitleAgeSince
Adam Levy CEO
 Chief Executive Officer 60 2019
Adam Drapczuk DFI
 Director of Finance/CFO 47 2021
Gregory J. Robb COO
 Chief Operating Officer - -
Members of the board TitleAgeSince
Scott Henry BRD
 Director/Board Member 52 Jan. 15
Nachum Stein BRD
 Director/Board Member 74 2019
Dave Stefansky BRD
 Director/Board Member 51 2019
More insiders

Quotes

Date Price Change Volume
23-12-04 2.1 +0.48% 4 229
23-12-01 2.09 +10.58% 90,885
23-11-30 1.89 +5.00% 7,015
23-11-29 1.8 +2.27% 6,051
23-11-28 1.76 -5.63% 10,234

Delayed Quote Nasdaq, December 04, 2023 at 10:12 am EST

More quotes

Company Profile

NexGel, Inc. is a provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. The Company is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its gels and its consumer products are manufactured using proprietary and non-proprietary mixing, coating, and crosslinking technologies. Its hydrogels are marketed in the United States and abroad by its customers. The Company markets under the brand names MedaGel and LumaGel Beauty. The products it sells under its MedaGel brand primarily relate to over the counter (OTC) remedy solutions, such as blister and pain applications; while the products it sells under its LumaGel Beauty brand primarily relate to beauty and cosmetic solutions, such as wrinkle and skin cream applications.
Sector
Pharmaceuticals
Calendar
2024-03-17 - Q4 2023 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for NEXGEL, Inc.

Trading Rating :
Investor Rating :
ESG Refinitiv :
-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.09USD
Average target price
6USD
Spread / Average Target
+187.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NEXGEL, INC. Stock NEXGEL, Inc.
+68.00% 12 M $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+58.03% 525 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+46.76% 454 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-9.97% 381 B $
MERCK & CO., INC. Stock Merck & Co., Inc.
-6.09% 262 B $
ABBVIE INC. Stock AbbVie Inc.
-10.88% 253 B $
ROCHE HOLDING AG Stock Roche Holding AG
-15.32% 221 B $
NOVARTIS AG Stock Novartis AG
+2.61% 202 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-8.84% 200 B $
PFIZER, INC. Stock Pfizer, Inc.
-43.03% 163 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock NEXGEL, Inc. - Nasdaq
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer